文献速递消化内镜

退伍军人事务医疗系统内镜前COVID-19筛查与SARS-CoV-2核酸检测的临床实践模式、结局及与操作量的关系

Pre-endoscopy coronavirus disease 2019 screening and severe acute respiratory syndrome coronavirus-2 nucleic acid amplification testing in the Veterans Affairs healthcare system: clinical practice patterns, outcomes, and relationship to procedure volume.
PubMed 文献 · Gastrointest Endosc · 2022-04-22

该研究分析了2020年3月至2021年4月退伍军人事务医疗系统的内镜前COVID-19症状和暴露筛查及SARS-CoV-2核酸检测数据,共纳入220,891例完成的内镜检查。结果显示筛查灵敏度34.6%、特异度96.4%,核酸检测阳性率1.8%,每月检测量与内镜操作量之间相关性极弱(Spearman秩相关系数=0.09)。

要点

  • 完成的内镜检查中52.5%有筛查记录,69.8%有术前7天内核酸检测结果。
  • 筛查灵敏度34.6%、特异度96.4%,阳性预测值15.0%,阴性预测值98.7%。
  • 每月检测量与内镜操作量之间相关性极弱(Spearman秩相关系数=0.09)。

核心结论

  • 研究结果对程序前检测决策有重要启示,尤其考虑到SARS-CoV-2 delta和omicron变异株流行期间接种疫苗者突破性感染的情况。

研究设计与样本

  • 分析2020年3月至2021年4月退伍军人事务医疗系统的COVID-19筛查和核酸检测结果,以确定使用情况、筛查性能特征及检测与内镜操作量趋势的关联。

主要发现

  • 在220,891例完成的内镜检查中,115,890例(52.5%)有术前COVID-19症状和暴露筛查记录,154,127例(69.8%)有术前7天内核酸检测结果。
  • 在131,894例取消的内镜检查中,26,475例(20.1%)有筛查数据,28,505例(21.6%)有SARS-CoV-2核酸检测结果。
  • 所有受检者中核酸检测阳性率为1.8%,筛查阴性者中阳性率为1.3%。
  • 与核酸检测相比,COVID-19筛查的灵敏度为34.6%(95%CI 32.4%-36.8%),特异度为96.4%(95%CI 96.2%-96.5%),阳性预测值为15.0%(95%CI 14.0%-16.1%),阴性预测值为98.7%(95%CI 98.7%-98.8%)。
  • 每月检测量与每月内镜操作量之间呈极弱相关(Spearman秩相关系数=0.09)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The coronavirus disease 2019 (COVID-19) pandemic has had profound impacts worldwide, including on the performance of GI endoscopy. We aimed to describe the performance and outcomes of pre-endoscopy COVID-19 symptom and exposure screening and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) nucleic acid amplification testing (NAAT) across the national Veterans Affairs healthcare system and describe the relationship of SARS-CoV-2 NAAT use and resumption of endoscopy services. METHODS: COVID-19 screening and NAAT results from March 2020 to April 2021 were analyzed to determine use, performance characteristics of screening, and association between testing and endoscopic volume trends. RESULTS: Of 220,891 completed endoscopies identified, 115,890 (52.5%) had documented preprocedure COVID-19 symptom and exposure screenings and 154,127 (69.8%) had preprocedure NAAT results within 7 days before scheduled endoscopy. Of 131,894 total canceled endoscopies, 26,475 (20.1%) had screening data and 28,505 (21.6%) had SARS-CoV-2 NAAT results. Overall, positive NAAT results were reported in 1.8% of all individuals tested and in 1.3% of those who screened negative. Among completed and canceled endoscopies, COVID-19 screening had a 34.6% sensitivity (95% confidence interval [CI], 32.4%-36.8%) and 96.4% specificity (95% CI, 96.2%-96.5%) when compared with NAAT. COVID-19 screening had a positive predictive value of 15.0% (95% CI, 14.0%-16.1%) and a negative predictive value of 98.7% (95% CI, 98.7%-98.8%). There was a very weak correlation between monthly testing and monthly endoscopy volume by site (Spearman rank correlation coefficient = .09). CONCLUSIONS: These findings have important implications for decisions about preprocedure testing, especially given breakthrough infections among vaccinated individuals during the SARS-CoV-2 delta and omicron variant surge.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Gawron AJ, Sultan S, Glorioso TJ, et al. Pre-endoscopy coronavirus disease 2019 screening and severe acute respiratory syndrome coronavirus-2 nucleic acid amplification testing in the Veterans Affairs healthcare system: clinical practice patterns, outcomes, and relationship to procedure volume. Gastrointest Endosc. 2022. PMID: 35461889. doi:10.1016/j.gie.2022.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。